Tralokinumab (Adbry ®)

Selected references.

- Deleuran M, et al. 2024. Systemic anti-inflammatory treatment of atopic dermatitis during conception, pregnancy and breastfeeding: Interdisciplinary expert consensus in Northern Europe. J Eur Acad Dermatol Venereol 38:31-41.
- Product Information. 2021. ADBRY(TM) subcutaneous injection, tralokinumab-ldrm subcutaneous injection. LEO Pharma Inc.
- Stratigakis A, et al. 2023. A regression approach for assessing large molecular drug concentration in breast milk. Reprod Breed;3:199-207.

¿Preguntas? Llame al 866.626.6847 | Texto 855.999.3525 | Correo electrónico o chat en MotherToBaby.org .

Descargo de responsabilidad: las hojas informativas de MotherToBaby están destinadas a fines de información general y no deben reemplazar los consejos de su proveedor de atención médica. MotherToBaby es un servicio de la Organización sin fines de lucro de Especialistas en Información de Teratología (OTIS). Copyright de OTIS, 1 de septiembre de 2024.

Tralokinumab (Adbry ®)

Selected References:

- Allan KM, et al. 2015. Maternal vitamin D and E intakes during pregnancy are associated with asthma in children. Eur Respir J. 2015 Apr;45(4):1027-1036.
- Ashraf M, et al. 2020. Changes in vitamin E levels as a marker of female infertility. J Pak Med Assoc 70(10): 1762-1766.
- Beers MH, et al. 1999. Merck Manual Diagnosis & Therapy, 17th ed., 2833.
- Boskovic R, et al. 2005. Pregnancy outcome following high doses of vitamin E supplementation. Reprod Toxicol 20:85-88.
- Gilboa SM, et al. 2014. National Birth Defects Prevention Study. Maternal intake of vitamin E and birth defects,

national birth defects prevention study, 1997 to 2005. Birth Defects Res A Clin Mol Teratol. 100(9):647-657.

- Gross SJ, Gabriel E. 1985. Vitamin E status in preterm infants fed human milk or infant formula. J Pediatr 106:635-639.
- Gyorgy P, et al. 1952. Availability of vitamin E in the newborn infant. Proc Soc Exp Biol Med 81:536-538.
- Hook EB, et al. 1074. Vitamin E, Teratogen or anti-teratogen? Lancet 1:809.
- Kanno C, et al. 1989. Transfer of orally administered alpha-tocopherol into human milk. J Nutr Sci Vitaminol (Tokyo) 35:649-653.
- Martinez Fe, et al. 1984. Evaluation of plasma tocopherols in relation to hematological indices of Brazilian infants on human milk and cow's milk regime from birth to 1 year of age. Am J Clin Nutr 39:969-974.
- Maslova E, et al. 2014. 2014. Maternal intake of vitamins A, E and K in pregnancy and child allergic disease: a longitudinal study from the Danish National Birth Cohort. British J Nutr 111: 1096-1108.
- Mino M, Nishino H. 1973. Fetal and maternal relationship in serum vitamin E level. J Nutr Sci Vitaminol 19:475-482.
- National Institutes of Health Office of Dietary Supplements. 2021. Vitamin E: Fact Sheet for Health Professionals. Available at: https://ods.od.nih.gov/factsheets/VitaminE-HealthProfessional/. Accessed 3 July 2024.
- Scholl TO, et al. 2006. Vitamin E: maternal concentrations are associated with fetal growth. Am J Clin Nutr 84(6):1442-1448.
- Smedts HP, et al. 2009. High maternal vitamin E intake by diet or supplements is associated with congenital heart defects in the offspring. BJOG. 116(3):416-423.
- Ruder EH, et al. 2014. Female dietary antioxidant intake and time to pregnancy among couples treated for unexplained infertility. Fertil Steril 101(3): 759-766.
- Wu H, et al. 2018. Does vitamin E prevent asthma or wheeze in children: A systematic review and meta-analysis. Paediatr Respir Rev. 27:60-68.
- XI Y, et al. 2022. Vitamin E concentration in breast milk in different periods of lactation: meta-analysis. Front Nutr 9: 1050011.

Descargo de responsabilidad: las hojas informativas de MotherToBaby están destinadas a fines de información general y no deben reemplazar los consejos de su proveedor de atención médica. MotherToBaby es un servicio de la Organización sin fines de lucro de Especialistas en Información de Teratología (OTIS). Copyright de OTIS, 1 de septiembre de 2024.

Tralokinumab (Adbry ®)

Selected References

- Bruckmaier R, et al. 1991. Effects of alpha- and beta-adrenergic agonists in intramammary pressure and milk flow in dairy cows. J Dairy Res. 58:411-419.
- Cottle MKW, et al. 1982. Effects of phenylephrine and sodium salicylate on maternal and fetal cardiovascular indices and blood oxygenation in sheep. Am J Obstet Gynecol. 143:170-176.
- Gilbert-Barness E, Drut RM. 2000. Association of sympathomimetic drugs with malformations. Vet Hum Toxicol. 42:168-171.
- Heinonen OP, et al. 1977. Birth Defects and Drugs in Pregnancy, Littleton, Publishing Sciences Group, pp 345-356, 439, 476, 491.
- Mohta M, et al. 2022. Neonatal outcomes following phenylephrine or norepinephrine for treatment of spinal anesthesia-induced hypotension at emergency cesarean section in women with fetal compromise: a randomised controlled study. Int J of Obstet Anesthesia 49:103247.
- Rothman KJ, et al. 1979. Exogenous hormones and other drug exposures of children with congenital heart disease. Am J Epidemiol. 109:433-439.
- Schatz M, et al. 1997. Asthma and allergy in pregnancy. Clin Perinatol. 24(2):407-432.
- Ugen KE, Scott WJ Jr. 1987. Reduction of uterine blood flow by phenylephrine, an alpha-adrenergic agonist, in the day 11 pregnant rat: relationship to potentiation of acetazolamide teratogenesis. Teratology. 36(1):133-141.
- Yau W-P, et al. 2013. Use of decongestants during pregnancy and the risk of birth defects. Am J Epidemiol. 178(2):198-208.
- Werler MM, et al. 2003. Association of vasoconstrictive exposures with risks of gastroschisis and small intestinal atresia. Epidemiology. 14(3):349-354.
- Werler MM, et al. 2002. Maternal medication use and risks of gastroschisis and small intestinal atresia. Am J Epidemiol. 155(1):26-31.
- Werler MM, et al. 2004. Vasoactive exposures, vascular events, and hemifacial microsomia. Birth Defects Res A Clin Mol Teratol 70(6):389-395.
- Zierler S, Rothman KJ. 1985. Congenital heart disease in relation to maternal use of Bendectin and other drugs in early pregnancy. N Engl J Med. 313:347-352

Descargo de responsabilidad: las hojas informativas de MotherToBaby están destinadas a fines de información general y no deben reemplazar los consejos de su proveedor de atención médica. MotherToBaby es un servicio de la Organización sin fines de lucro de Especialistas en Información de Teratología (OTIS). Copyright de OTIS, 1 de septiembre de 2024.

Tralokinumab (Adbry ®)

Selected References:

- Ahn HK, et al. 2007. Exposure to amlodipine in the first trimester of pregnancy and during breastfeeding. Hypertension in pregnancy, 26(2):179–187.
- Aoki H, et al. 2018. Low Levels of Amlodipine in Breast Milk and Plasma. Breastfeeding medicine,13(9):622–626.
- Centers for Disease Control and Prevention. (2024). Health and economic benefits of high blood pressure interventions. Retrieved August 2024 from https://www.cdc.gov/nccdphp/priorities/high-blood-pressure.html.
- Faham DE, et al. 2019. Can Amlodipine Improve the Pre-ovulatory Follicle Blood Flow in Women with Polycystic Ovarian Syndrome?. Journal of reproduction & infertility, 20(2):89–94.
- Ishikawa T, et al. 2023. Risk of major congenital malformations associated with first-trimester antihypertensives, including amlodipine and methyldopa: A large claims database study 2010-2019. Pregnancy hypertension, 31:73–83.
- Magee LA, et al. 1996. The safety of calcium channel blockers in human pregnancy: a prospective, multicenter cohort study. Am J Obstet Gynecol, 174(3):823-828.
- Mito AA, et al. 2019. Safety of Amlodipine in Early Pregnancy. Journal of the American Heart Association, 8(15):1-7.
- Morgan JL, et al. 2018. Pharmacokinetics of amlodipine besylate at delivery and during lactation. Pregnancy hypertension, 11:77–80.
- Naito T, et al. 2015. Amlodipine passage into breast milk in lactating women with pregnancy-induced hypertension and its estimation of infant risk for breastfeeding. Journal of human lactation, 31(2):301–306.
- Rosbotham JL, et al. 1998. Painful subcutaneous fat necrosis of the newborn associated with intra-partum use of a calcium channel blocker. Clinical and experimental dermatology. 23(1):19–21.
- Szucs KA, et al. 2010. Maternal membranous glomerulonephritis and successful exclusive breastfeeding. Breastfeeding Medicine, 5(3):123–126.
- S. Food and Drug Administration. (2011). Norvasc (Amlodipine besylate) tablets label. Retrieved August 2024 from https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/019787s047lbl.pdf.
- Vigil-De Gracia P, et al. 2014. Management of chronic hypertension during pregnancy with furosemide, amlodipine or aspirin: a pilot clinical trial. The journal of maternal-fetal & neonatal medicine: the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians, 27(13): 1291–1294.
- Yin J, et al. 2022. Nifedipine or amlodipine? The choice for hypertension during pregnancy: a systematic review and meta-analysis. Archives of Gynecology and Obstetrics, 306(6):1891–1900.

Descargo de responsabilidad: las hojas informativas de MotherToBaby están destinadas a fines de información general y no deben reemplazar los consejos de su proveedor de atención médica. MotherToBaby es un servicio de la Organización sin fines de lucro de Especialistas en Información de Teratología (OTIS). Copyright de OTIS, 1 de septiembre de 2024.

Tralokinumab (Adbry ®)

Selected References:

- Auffret M, et al. 2016. Misoprostol exposure during the first trimester of pregnancy: Is the malformation risk varying depending on the indication? Eur J Obstet Gynecol Reprod Biol, 207:188-192.
- Baev OR, et al. 2017. Outcomes of mifepristone usage for cervical ripening and induction of labour in full-term pregnancy. Randomized controlled trial. Eur J Obstet Gynecol Reprod Biol, 217:144-149.
- Brown A, et al. 2002. Daily low dose mifepristone has contraceptive potential by suppressing ovulation and menstruation: a double-blind randomised controlled trial of 2 and 5 mg per day for 120 days. J Clin Endocrinol Metab, 87:63-70.
- Bos-Thompson MA, et al. 2008. Mobius syndrome in a neonate after mifepristone and misoprostol elective abortion failure. Ann Pharmacother, 42(6):888-892.
- Chen A, et al. 2004. Mifepristone-induced early abortion and outcome of subsequent wanted pregnancy. Am J Epidemiol, 160(2):110-117.
- Gary MM, Harrison DJ. 2006. Analysis of severe adverse events related to the use of mifepristone as an abortifacient. Ann Pharmacother, 40:191-197.
- Glasier A, et al. 1992. Mifepristone (RU 486) compared with high-dose estrogen and progestogen for emergency postcoital contraception. N Engl J Med, 327:1041-1044.
- Juneja SC, Dodson MG. 1990. In vitro effect of RU 486 on sperm-egg interaction in mice. Am J Obstet Gynecol, 163:216-221.
- Lakha F, et al. 2007. A novel estrogen-free oral contraceptive pill for women: multicentre, double-blind, randomized controlled trial of mifepristone and progestogen-only pill (levonorgestrel). Hum Reprod, 22(9):2428-2436.
- Liao H, et al. 2011. Repeated medical abortions and the risk of preterm birth in the subsequent pregnancy. Arch Gynecol Obstet, 284(3):579-586.
- Lim BH, et al. 1990. Normal development after exposure to mifepristone in early pregnancy. Lancet, 336:257-258.
- Mifepristone Drug Label. 2023. Available at: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b63fad9b-7f12-4400-9019-b0586054e534.
- Peyron R, et al. 1993. Early termination of pregnancy with mifepristone (RU 486) and the orally active prostaglandin misoprostol. N Engl J Med, 328:1509-1513.
- Pons JC, et al. 1991. Development after exposure to mifepristone in early pregnancy. Lancet; 338:763.
- Saav I, et al. 2010. Medical abortion in lactating women–low levels of mifepristone in breast milk. Acta Obstet Gynecol Scand, 89(5):618-622.
- Sanchez-Criado JE, et al. 1990. A possible dual mechanism of the anovulatory action of antiprogesterone RU486 in the rat. Biol Reprod, 42:877-886.

- Shoupe D, et al. 1987. Effects of the antiprogesterone RU 486 in normal women. II. Administration in the late follicular phase. Am J Obstet Gynecol, 157:1421-1426.
- Sitruk-Ware R, Davey A, Sakiz E. 1998. Fetal malformations and failed medical termination of pregnancy. Lancet, 352:323.
- Swahn ML, et al. 1996. Contraception with anti-progesterone. Baillieres Clin Obstet Gynaecol, 10(1):43-53.
- Task force on postovulatory methods of fertility regulation. 1999. Comparison of three single doses of mifepristone as emergency contraception: a randomised trial. Lancet 353:607-702.
- van der Schoot P, et al.1987. Effects of the progesterone antagonist RU486 on ovarian activity in the rat. Endocrinology, 121:1375-1382.
- Wolf JP. et al. 1990. Tolerance of perinidatory primate embryos to RU 486 exposure in vitro and in vivo. Contraception, 41:85-92.
- Yang YQ, Wu JT. 1990. RU 486 interferes with egg transport and retards the in vivo and in vitro development of mouse embryos. Contraception, 41:551-556.
- Zhu QX, et al. 2009. Mifepristone-induced abortion and placental complications in subsequent pregnancy. Hum Reprod, 24(2):315-319.

¿Preguntas? Llame al 866.626.6847 | Texto 855.999.3525 | Correo electrónico o chat en MotherToBaby.org .

Descargo de responsabilidad: las hojas informativas de MotherToBaby están destinadas a fines de información general y no deben reemplazar los consejos de su proveedor de atención médica. MotherToBaby es un servicio de la Organización sin fines de lucro de Especialistas en Información de Teratología (OTIS). Copyright de OTIS, 1 de septiembre de 2024.